GYRE THERAPEUTICS INC (GYRE)
US4037831033 - Common Stock
GYRE gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. GYRE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. GYRE has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year GYRE has reported negative net income.
In the past year GYRE had a positive cash flow from operations.
GYRE had negative earnings in each of the past 5 years.
In the past 5 years GYRE reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of GYRE (-61.45%) is comparable to the rest of the industry.
With a Return On Equity value of -121.81%, GYRE perfoms like the industry average, outperforming 40.40% of the companies in the same industry.
GYRE has a better Return On Invested Capital (31.09%) than 99.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.45% | ||
| ROE | -121.81% | ||
| ROIC | 31.09% |
ROA(3y)-88.87%
ROA(5y)-76.38%
ROE(3y)-158.6%
ROE(5y)-126.1%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GYRE has a Operating Margin of 22.74%. This is amongst the best in the industry. GYRE outperforms 96.59% of its industry peers.
GYRE's Gross Margin of 96.16% is amongst the best of the industry. GYRE outperforms 96.41% of its industry peers.
In the last couple of years the Gross Margin of GYRE has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.74% | ||
| PM (TTM) | N/A | ||
| GM | 96.16% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.45%
GM growth 5YN/A
2. Health
2.1 Basic Checks
GYRE has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for GYRE has been increased compared to 1 year ago.
The number of shares outstanding for GYRE has been increased compared to 5 years ago.
GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 12.03 indicates that GYRE is not in any danger for bankruptcy at the moment.
GYRE has a Altman-Z score of 12.03. This is amongst the best in the industry. GYRE outperforms 87.61% of its industry peers.
There is no outstanding debt for GYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.03 |
ROIC/WACC2.93
WACC10.61%
2.3 Liquidity
A Current Ratio of 3.72 indicates that GYRE has no problem at all paying its short term obligations.
GYRE has a Current ratio of 3.72. This is comparable to the rest of the industry: GYRE outperforms 43.63% of its industry peers.
GYRE has a Quick Ratio of 3.29. This indicates that GYRE is financially healthy and has no problem in meeting its short term obligations.
GYRE has a Quick ratio (3.29) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.72 | ||
| Quick Ratio | 3.29 |
3. Growth
3.1 Past
GYRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.89%, which is quite impressive.
The Revenue has grown by 14260.76% in the past year. This is a very strong growth!
GYRE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 547.08% yearly.
EPS 1Y (TTM)98.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.12%
Revenue 1Y (TTM)14260.76%
Revenue growth 3Y75.61%
Revenue growth 5Y547.08%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, GYRE will show a very strong growth in Earnings Per Share. The EPS will grow by 33.78% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y118.65%
EPS Next 2Y50.41%
EPS Next 3Y33.78%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
GYRE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 16.81, GYRE is valued correctly.
GYRE's Price/Forward Earnings ratio is rather cheap when compared to the industry. GYRE is cheaper than 95.33% of the companies in the same industry.
GYRE's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.69.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 16.81 |
4.2 Price Multiples
GYRE's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GYRE is cheaper than 95.15% of the companies in the same industry.
94.79% of the companies in the same industry are more expensive than GYRE, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.9 | ||
| EV/EBITDA | 21.35 |
4.3 Compensation for Growth
GYRE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
GYRE's earnings are expected to grow with 33.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.41%
EPS Next 3Y33.78%
5. Dividend
5.1 Amount
No dividends for GYRE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GYRE THERAPEUTICS INC
NASDAQ:GYRE (1/3/2025, 8:00:01 PM)
10.79
-1.21 (-10.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.37%
Inst Owner Change28.14%
Ins Owners6.19%
Ins Owner Change0%
Market Cap1.01B
Analysts82.86
Price TargetN/A
Short Float %3.51%
Short Ratio8.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DP16.63%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 16.81 | ||
| P/S | 5.27 | ||
| P/FCF | 38.9 | ||
| P/OCF | 27.34 | ||
| P/B | 15.97 | ||
| P/tB | 16.02 | ||
| EV/EBITDA | 21.35 |
EPS(TTM)-0.23
EYN/A
EPS(NY)0.64
Fwd EY5.95%
FCF(TTM)0.28
FCFY2.57%
OCF(TTM)0.39
OCFY3.66%
SpS2.05
BVpS0.68
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.45% | ||
| ROE | -121.81% | ||
| ROCE | 39.36% | ||
| ROIC | 31.09% | ||
| ROICexc | 40.23% | ||
| ROICexgc | 40.31% | ||
| OM | 22.74% | ||
| PM (TTM) | N/A | ||
| GM | 96.16% | ||
| FCFM | 13.56% |
ROA(3y)-88.87%
ROA(5y)-76.38%
ROE(3y)-158.6%
ROE(5y)-126.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.45%
GM growth 5YN/A
F-Score6
Asset Turnover1.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 80.83% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.72 | ||
| Quick Ratio | 3.29 | ||
| Altman-Z | 12.03 |
F-Score6
WACC10.61%
ROIC/WACC2.93
Cap/Depr(3y)355.37%
Cap/Depr(5y)293.22%
Cap/Sales(3y)6.16%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.12%
EPS Next Y118.65%
EPS Next 2Y50.41%
EPS Next 3Y33.78%
EPS Next 5YN/A
Revenue 1Y (TTM)14260.76%
Revenue growth 3Y75.61%
Revenue growth 5Y547.08%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y421.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y152.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y174.87%
OCF growth 3YN/A
OCF growth 5YN/A